Shots:
- The first patient was dosed with iadademstat (ORY-1001) + venetoclax + azacitidine combination to treat AML naïve patients (n=45) under the P-I trial to evaluate the safety, tolerability, preliminary efficacy & optimal dose. Trial will be managed & funded by NCI under CRADA
- In addition, the combination is being evaluated to treat 1L AML in an IIT P-I trial at OHSU Knight Cancer Institute, plus iadademstat is also being assessed with gilteritinib in a company-funded P-Ib trial to treat r/r FLT3mut+ AML
- Iadademstat (oral small molecule) inhibits the interaction of LSD1 enzyme with GFI-1 transcription factor to prevent disease progression in leukemia
Ref: GlobeNewswire | Image: Oryzon
Related News:- Bayer Reports the US FDA’s sNDA Acceptance of Nubeqa (Darolutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
